论文部分内容阅读
近年来,由于诊断方面的进步,肝癌手术切除率不断提高。此外,经导管动脉栓塞治疗,进一步延长了肝癌患者的生存期。因残留部分癌组织或多中心病灶致病变复发或转移者,可选用化疗加栓塞疗法,并在此基础上并用免疫疗法是颇有前途的治疗手段。 一、肝癌与免疫 高龄者癌症发病率高,可能系年龄老化,以胸腺为主的淋巴组织萎缩以致免疫力减低所致。但是否存在对癌症的特异免疫,尚未明确。Carison等(1985)通过制作单克隆抗体研究抗原性,证实存在肝细胞癌的特异抗原。藤本重义(1982)报道,癌组织周围抑制性/细胞毒性T细胞亚型的比值增高。癌病灶边缘抑制细胞增
In recent years, due to advances in diagnostics, the rate of surgical resection of liver cancer has continued to increase. In addition, transcatheter arterial embolization further prolongs the survival of patients with liver cancer. Recurrence or metastasis of the disease due to residual part of the cancer tissue or multicenter lesions, chemotherapy and embolization can be used, and on the basis of combined use of immunotherapy is a promising treatment. I. Liver Cancer and Immunity Older people have a high incidence of cancer, which may be due to aging. The loss of immunity is caused by atrophy of the lymphatic tissue, which is mainly thymus. However, it is not clear whether there is a specific immunity to cancer. Carison et al. (1985) studied the antigenicity by making monoclonal antibodies to confirm the presence of specific antigens for hepatocellular carcinoma. Fujimoto Saga (1982) reported that the ratio of suppressor/cytotoxic T cell subtypes around cancer tissue increased. Increased marginal inhibition of cancerous cells